Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review-Reference-Cited by-同舟云学术

Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review

Published:2023-04 Issue:11 Volume:19 Page:789-810
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Heuser Michael¹^ORCID,Fernandez Cédric²^ORCID,Hauch Ole³^ORCID,Klibanov Olga M⁴^ORCID,Chaudhary Tanushree⁵^ORCID,Rives Vincent²^ORCID

Affiliation:

1. Department of Hematology, Hemostasis, Oncology & Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

2. Servier International, 92284, Suresnes, France

3. Hauch Consultancy, 1060, Brussels, Belgium

4. IQVIA, Medical and Patient Communications, Parsippany, NJ 07054, USA

5. IQVIA, Real World Evidence, Gurugram, Haryana 12002, India

Abstract

Aim: To review clinical evidence for current and emerging treatments for patients with acute myeloid leukemia (AML) who are ineligible for first-line induction chemotherapy. Methods: A systematic literature review was performed (28 October 2021) to identify clinical outcomes including overall survival (OS), event-free survival (EFS), relapse-free survival (RFS) and adverse events (AEs). Results: Of 233 references that met prespecified criteria, 26 studies were included. Adding targeted therapies (venetoclax/ivosidenib) to hypomethylating agents (HMAs) yielded better OS hazard ratios (HRs) (0.44–0.66) and EFS HRs (0.33–0.63) compared with other agents. AEs were more frequent with combination therapies than control arms, except with ivosidenib plus azacitidine. Conclusion: Targeted therapy combined with a HMA shows the most promising results in this difficult-to-treat population.

Funder

Servier International

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-1286

Reference107 articles.

1. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’

2. Drug therapy for acute myeloid leukemia

3. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

4. Cancer.net. Leukemia - Acute Myeloid - AML: statistics. www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics (Accessed August 23, 2022).

5. The Economist Intelligence Unit. Acute Myeloid leukemia: mapping the policy response to an acute cancer in France, Germany, Italy, Spain and the UK. https://worldcancerinitiative.economist.com/pdf/acute-myeloid-leukemia/acute-myeloid-leukemia-report.pdf (Accessed 23 August 2022).